Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Secretary/CEO of subsidiary | May 10, 2021 | May 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date May 10, 2021 · Filed May 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,752,703 |
Ending reported balance
After 2021-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-05-10 · Exercise / conversion · Acquired 103,500 · Balance 1,796,955 F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. Row 2 · 2021-05-11 · Sale · Disposed 44,252 · Balance 1,752,703 F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 207,000 |
Reported balance
After 2021-05-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-10 · Exercise / conversion · Disposed 103,500 · Balance 207,000 F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021. F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,582,373 |
Reported balance
Holding disclosure · report date 2021-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,582,373 F3: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021.
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.
F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2018 Filed Oct 11, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-005414 · milligan-form4_100918.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 23:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005028 · milligan-form4_092518.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,532,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 23:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $6.78 | $847,000.00 |
DisclosureSEC source: 0001387131-18-005028 · milligan-form4_092518.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.7 to $6.88, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 23:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-005028 · milligan-form4_092518.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 23:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005028 · milligan-form4_092518.xml · derivative · entry 7 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 23:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $6.78 | $847,250.00 |
DisclosureSEC source: 0001387131-18-005028 · milligan-form4_092518.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.61 to $6.885, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 23:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-005028 · milligan-form4_092518.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · derivative · entry 9 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,782,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $6.13 | $765,750.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.03 to $6.22, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · derivative · entry 8 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907,255 Underlying: Common Stock · 125,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 125,000 | $6.07 | $758,125.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · nonDerivative · entry 2 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,419 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.245, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 125,000 | $0.10 | $12,725.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · nonDerivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 434,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · nonDerivative · entry 6 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 434,814 F5 · ownership.nature: By the Milligan Irrevocable Nonexempt Trust - 2014. These securities are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 23, 2018 Filed Sep 13, 2018 00:19 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 434,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-004676 · milligan-form4_091018.xml · nonDerivative · entry 5 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F4 · ownership.nature: By the Reporting Person's Grantor-Retained Annuity Trust (the "GRAT"). Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 21:37 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 270,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001387131-18-001119 · milligan-form4_031518.xml · derivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: Underlying shares vest as follows: 90,000 shares on the first anniversary date of the grant, 90,000 shares on the second anniversary date of the grant, and 90,000 shares on the third anniversary date of the grant. Read SEC document |
| November 29, 2017 Filed Feb 13, 2018 02:18 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000566 · milligan-form5_123117.xml · nonDerivative · entry 4 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 2,987,523 F3 · balance_after: Includes 317,127 shares of common stock previously reported as being held indirectly by the GRAT. F2 · ownership.nature: By John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:41 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-qualified stock option (right to buy) · Derivative | 260,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001387131-17-001465 · milligan-form4_031517.xml · derivative · entry 1 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Underlying shares vest as follows: 86,667 shares on the first anniversary date of the grant, 86,667 shares on the second anniversary date of the grant, and 86,666 shares on the third anniversary date of the grant. Read SEC document |
| March 02, 2017 Filed Feb 13, 2018 02:18 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000566 · milligan-form5_123117.xml · nonDerivative · entry 3 Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See Disclosed balance after: 2,690,396 F2 · ownership.nature: By John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.